In line with this, a recent study by Rao et al. reported that the anti-PD-1 treatment can trigger an anti-tumor immune response even in the total absence of CD8+T cells in CD8−/− GBM preclinical models [51]. The gene discussed is PDCD1; the disease is neoplasm.